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Abstract 
 
The medicinal plants Aristolochia clematitis L. as well as Asarum europaeum L., 
representatives of the plant family Aristolochiaceae and mentioned in the German 
Homeopathic Pharmacopoeia, contain aristolochic acid. We found that the mother tinctures of 
A. clematitis and A. europaeum inhibited DNA synthesis in human hepatoma HepG2 cells in a 
dose-dependent manner. One of the components of the plant extract, aristolochic acid I (AAI), 
is linked to the development of nephropathy and urothelial cancer in humans. Therefore, we 
also evaluated the cytotoxicity and genotoxicity of AAI in HepG2 cells. Cell proliferation was 
inhibited concentration-dependently by AAI using BrdU-ELISA and colony forming assay. 
AAI formed DNA adducts (measured by 32P-postlabeling), induced chromosomal aberrations 
(micronuclei) and DNA strand breaks. DNA damage induced by AAI led to an arrest of cells 
in the S-phase which was associated with the increased expression of p53 and p21 proteins. 
The results are discussed under consideration of former studies. 
 
Key words: Aristolochic acid I; HepG2 cells; DNA damage; Aristolochia clematitis; Asarum 
europaeum 
 
Abbreviations: AAI, aristolochic acid I; HAB, German Homeopathic Pharmacopoeia; NQO1, 
NAD(P)H:quinone oxidoreductase 
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1. Introduction 
 
In the German Homeopathic Pharmacopoeia (Homöopathisches Arzneibuch, HAB) 
the medicinal plants Aristolochia clematitis L. as well as Asarum europaeum L. are listed. 
The homeopathic tinctures of A. clematitis are used e.g. for the treatment of the upper and 
lower respiratory tract, the urinary and gastro-intestinal tract as well as at gynecological 
indications. The homeopathic tinctures of A. europaeum are applied for diseases of the central 
nervous system, lower respiratory tract, the gastrointestinal tract, and for flu-like infection 
(HAB, 2010). Many herbs from the genus Aristolochia and several species of the genus 
Asarum, both members of the plant family Aristolochaceae, contain aristolochic acid (AA) 
(Hashimoto et al., 1999). AA is a mixture of structurally related nitrophenanthrene carboxylic 
acids, mainly aristolochic acid I (AAI) (Pailer et al., 1956). 
 AA has been shown to be nephrotoxic and carcinogenic in rodents (reviewed in Arlt et 
al., 2002b). In humans AA is the cause of Chinese herb nephropathy, now termed aristolochic 
acid nephropathy (AAN), which is characterized by renal interstitial fibrosis and associated 
with a high risk of urothelial cancer (Debelle et al., 2008; Nortier et al., 2000). The cause of 
this disease has been tracked to herbal medicinal remedies containing Aristolochia herbs and 
due to these findings, Aristolochia spp. and herbs, that can be confused or substituted for 
Aristolochia, have been banned in many countries. AA has also been shown to play a role in 
the development of Balkan endemic nephropathy (BEN) which affects residents in certain 
rural areas of Romania, Croatia, Bosnia, Serbia and Bulgaria along the Danube river basin 
(Arlt et al., 2002a; Grollman et al., 2007; Jelakovic et al., 2012; Schmeiser et al., 2012). The 
contamination of grain by seeds of A. clematitis, which occurs widely in the wheat fields of 
the Balkan region, is discussed to be a cause of BEN (Arlt et al., 2007; Grollman et al., 2007). 
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AA was recently classified as carcinogenic to humans (Group 1) by the International Agency 
for Research on Cancer (IARC) (Grosse et al., 2009).  
 The renal toxicity of AA and the development of urothelial carcinoma have been 
attributed primarily to AAI (Schmeiser et al., 2009; Shibutani et al., 2007). The genotoxic 
effect is based on the covalent binding of AAI to DNA after metabolic activation (Stiborova 
et al., 2008). In humans reductive bioactivation of AAI is attributed to NAD(P)H:quinone 
oxidoreductase (NQO1), cytochrome P450 (CYP) 1A1 and CYP1A2 (Stiborova et al., 2012; 
Stiborova et al., 2011). The proposed metabolic activation and DNA adduct formation of AAI 
is shown in Figure 1. AAI is activated by nitroreduction to N-hydroxyaristolactam I which 
can form an aristolactam-nitrenium ion as the ultimate carcinogen that binds to DNA, forming 
adducts. The structures of the major AAI-DNA adducts have been elucidated 
spectroscopically as 7-(deoxyadenosine-N6-yl)aristolactam I (dA-AAI) and 7-
deoxyguanosine-N2-yl)aristolactam I (dG-AAI) (Schmeiser et al., 2009). Translesion DNA 
synthesis past dA-AAI adducts generates predominantly A to T transversions, which is AA’s 
signature mutation (Arlt et al., 2007). It has been shown that characteristic A to T transversion 
mutations induced by AA lead to the activation of oncogenes (i.e. H-ras) in rodents or the 
inactivation of tumour suppressor genes (i.e. TP53) in humans (Chen et al., 2012; Grollman et 
al., 2007; Wang et al., 2012; Wang et al., 2011). Characteristic A to T transversion mutation 
induced by AA have also been observed in transgenic rodent mutations assays (Chen et al., 
2006; Kohara et al., 2002; McDaniel et al., 2012; Mei et al., 2006; Xing et al., 2012) as well 
as in immortalised Hupki (human TP53 knock-in) fibroblasts treated with AAI (Kucab et al., 
2010; Nedelko et al., 2009). 
The aim of the present study was to assess the cytotoxicity and genotoxicity of AAI in 
metabolically competent human hepatoma HepG2 cells (Westerink and Schoonen, 2007a, b). 
Assessment of genotoxicity was done by the 32P-postlabeling assay, alkaline comet assay and 
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micronucleus assay. Furthermore, the impact of AAI treatment on cell cycle progression 
(measured by FACS analysis), and on NQO1, p53 and p21 protein levels (determined by 
Western blotting) was analyzed. In addition, we also measured cell viability and cell 
proliferation of HepG2 cells treated with AAI or the mother tinctures A. clematitis and A. 
europaeum. 
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2. Materials and methods 
2.1. Chemicals 
RPMI 1640 medium, fetal bovine serum (FBS), L-alanyl-L-glutamine, trypsin, 
phosphate-buffered saline (PBS) were supplied by Biochrom (Berlin, Germany). Aristolochic 
acid I (AAI; as free acid) was purchased from Sigma-Aldrich (Steinheim, Germany). Mother 
tinctures according to HAB 2010 of Aristolochia clematitis and Asarum europaeum were 
obtained from the German Homeopathic Union (Deutsche Homöopathie-Union, DHU, 
Karlsruhe, Germany). Unless indicated otherwise all chemicals were products of Sigma-
Aldrich. 
 
2.2. Cell culture 
HepG2 cells were obtained from the German Collection of Microorganisms and Cell 
Cultures, Braunschweig, Germany. HepG2 cells were cultivated in a humidified 5% CO2 
atmosphere at 37°C in RPMI 1640 supplemented with 10% FBS and 1% L-alanyl-L-
glutamine. For experiments, cells were seeded into culture flasks or multi-well plates and 
adapted for 24 h. Stock solution of AAI (10 mg/mL) was prepared in DMSO. Controls were 
treated with DMSO only. In the experiments with the mother tinctures controls were handled 
with the corresponding ethanol / water mixture. 
 
2.3. Cell proliferation assay 
Cells were seeded in 96-well plates at a density of 2 × 104 cells per well. After 24 h of 
treatment with 0-20 µg/mL AAI and mother tinctures (up to 2.5% [v/v]), respectively, cells 
were labeled with BrdU for 2 h at 37°C. Cellular BrdU incorporation was measured using a 
cell proliferation ELISA BrdU colorimetric kit (Roche, Basel, Switzerland) according to the 
manufacturer’s instructions. Absorbances at 450 nm, referenced at 620 nm, were measured 
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using a SPECTRA Fluor microplate reader (Tecan, Switzerland). To reduce unspecific 
binding of the antibody conjugate cells were incubated with 1% BSA (Roth, Karlsruhe, 
Germany) for 30 min before antibody incubation. Cell proliferation was calculated as percent 
of control. 
 
2.4. Cell viability and colony forming ability 
7.5 × 105 cells were transferred into T25 flasks and cultivated for 24 h. Subsequently, 
cells were treated with 0-20 µg/mL AAI for 6 or 24 h, washed with PBS, trypsinized, 
collected in fresh medium and counted using a Casy Cell Counter (Schärfe Systems). 500 
cells per culture dish (60 mm) were seeded in triplicate into fresh medium for the 
determination of colony forming ability. After 14 days of incubation, colonies were fixed with 
ethanol, stained with Giemsa (Roth, Karlsruhe, Germany), counted and calculated as percent 
of control. 
 
2.5. DNA adduct analysis 
2.25 × 106 cells were seeded into T75 flasks and after 24 h exposed to 0-20 µg/mL 
AAI for 6 or 24 h. Subsequently, cells were harvested by trysinization. Centrifugation at 
400×g and a washing step with PBS yielded a cell pellet, which was stored at −20°C until 
DNA isolation. DNA was isolated using a standard phenol/chloroform extraction method. 
DNA adducts were determined for each DNA sample (4 µg) using the nuclease P1 enrichment 
version of the 32P-postlabeling method as described previously (Arlt et al., 2011; Phillips and 
Arlt, 2007). Chromatographic conditions for thin-layer chromatography (TLC) on 
polyethyleneimine-cellulose were: D1, 1.0 M sodium phosphate, pH 6.0; D2, 3.5 M lithium 
formiate, 8.5 M urea, pH 4.0; and D3, 0.8 M lithium chloride, 0.5 M Tris, 8.5 M urea, pH 9.0. 
TLC sheets were scanned by using a Packard Instant Imager (Dowers Grove, IL, USA). DNA 
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adduct levels (RAL, relative adduct labeling) were calculated from the adduct cpm, the 
specific activity of [γ-32P]ATP and the amount of DNA (pmol of DNA-P) used. Results were 
expressed as DNA adducts/108 nucleotides. 
 
2.6. Single-cell gel electrophoresis (comet assay) 
DNA strand breaks and formamidopyrimidine-DNA glycosylase (FPG)-sensitive sites 
were determined by the comet assay. The comet assay was performed essentially as described 
previously (Oya et al., 2011). Cells were seeded on six-well plates at a density of 3 × 105 cells 
per well. After treatment with 0-20 µg/mL AAI for 24 h cells were trypsinized, centrifuged 
and resuspended in fresh medium. Microscope slides were pre-coated with 1.5% agarose at 
least one day in advance. A fraction of cell suspension was embedded in 0.65% low melting 
point agarose (37°C) and the mixture was spread over a slide. Slides were then placed in lysis 
buffer (2.5 M NaCl, 0.1 M EDTA, 0.01 M Tris, 1% Triton X-100) overnight at 4°C in the 
dark. After lysis treatment, slides were placed in enzyme buffer, followed by the addition of 
either 60 µL enzyme buffer or 60 µL FPG enzyme (54 ng/µL). FPG was a generous gift of 
A.R. Collins (University of Oslo, Norway). Incubations were performed in a humidity 
chamber (37°C, 30 min). DNA unwinding was performed in alkaline buffer (0.3 M NaOH, 1 
mM EDTA) for 40 min at 4°C in the dark. Electrophoresis was performed (22 V, 24 min) 
using the same alkaline buffer. After electrophoresis, slides were neutralized, fixed in 
methanol and stained with ethidium bromide (10 µg/mL). Cover slips were placed over the 
slides for computerized image analysis using Comet Assay IV software (Perceptive 
Instruments, Haverhill, UK). All slides were coded before analysis. Fifty nuclei were assessed 
per slide, and tail intensity (% tail DNA) was used as the measure of DNA damage induced, 
as recommended (Collins et al., 2008). The average tail intensity of two replicate treatments 
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was calculated. To calculate the FPG-sensitive sites % tail DNA of FPG-untreated samples 
was subtracted from % tail DNA of FPG-treated samples. 
 
2.7. In vitro micronucleus assay 
3.75 × 105 cells were transferred into T12.5 flasks. Subsequently, cells were treated 
with AAI in two parallel cultures for 6 h (0-50 µg/mL) or 24 h (0-20 µg/mL). After treatment 
cells were washed with PBS and incubated with medium containing cytochalasin B (final 
concentration 3 µg/mL). 72 h after transfer cells were collected by trypsinization. Aliquots 
were centrifuged directly onto microscope slides using Thermo Megafuge 1.0 (115×g for 5 
min). Slides were fixed in 90% methanol for 10 min and stained with acridine orange (12.5 
mg/100 mL in PBS; Invitrogen, Oregon, USA). Slides were scored using a fluorescence 
microscope (Olympus, Hamburg, Germany). All slides were coded before analysis. 
Micronuclei, as defined by criteria summarized by Fenech (2007), were scored in 1000 
binucleated cells with two nuclei of approximately equal size. The replication index (RI) was 
calculated as RI = (((No. binucleated cells) + (2 × No. multinucleate cells)) ÷ (Total number 
of cells treated cultures) / ((No. binucleated cells) + (2 × No. multinucleate cells)) ÷ (Total 
number of cells control cultures)) × 100 (OECD, 2010). 
 
2.8. Flow cytometry 
For cell cycle analysis 7.5 × 105 cells were seeded into T25 flasks. After treatment 
with 0-20 µg/mL AAI for 24 h cells were harvested by trypsinization. The cell pellet was 
resuspended in 0.2 mL PBS and fixed in 2 mL 70% ethanol (−20°C). Samples were stored at 
−20°C at least overnight. For flow cytometry analysis cells were spun down and resuspended 
in 2 mL staining buffer containing 40 µg/mL propidium iodide (Invitrogen, UK) and 100 
µg/mL RNase A (Qiagen, Germany) in PBS. Cells were then incubated at 37°C for 1 h and 
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stored at 4°C overnight. Cell cycle analysis was performed using BD LSRII Flow Cytometer 
(BD Biosciences, UK). The relative number of cells in each phase of the cell cycle was 
determined using Cylchred and WinMDI v2.9 freeware (Hamouchene et al., 2011). 
 
2.9. Western blot analysis 
7.5 × 105 cells were seeded into T25 flasks. After treatment with 0-20 µg/mL AAI for 
24 h cells were rinsed with cold PBS, lysis buffer (62.5 mM Tris, 1 mM EDTA, 10% 
glycerine, 2% SDS) was added, the lysate was scraped from the surface and stored at −20°C 
until Western blot analysis. Cell lysates were electrophoretically separated using NuPage 4-
12% Bis-Tris SDS polyacrylamide gels (Invitrogen, UK). Following electrophoresis, gels 
were transferred onto a nitrocellulose membrane. The membrane was blocked in 4% non-fat 
dry milk (dissolved in Tris-buffered saline with 0.1% Tween). Blots were incubated with 
primary antibody and then with the species-specific horseradish peroxidase-conjugated 
secondary antibody (BioRad [anti-rabbit], Cell Signaling Technology [anti-mouse]). Bands 
were detected by chemiluminescence (West Pico Chemiluminescent Substrate, Thermo 
Scientific, USA). The monoclonal antibody against p53 (Ab-6) was purchased from 
Calbiochem (Darmstadt, Germany) and diluted 1:2000. Detection of p21 was done by 
monoclonal antibody purchased from BD Bioscience (Oxford, UK), diluted 1:2000. For 
detection of NQO1 a polyclonal antibody in a 1:20,000 dilution from Abcam (Cambridge, 
UK) was used. Monoclonal antibody to detect β-actin (AC-15) was also purchased from 
Abcam (Cambridge, UK), diluted 1:25,000 and used as loading control. 
 
2.10. HPLC-UV analysis 
Quantitative determination of AAI in the mother tincture was performed using high 
performance liquid chromatography (HPLC). HPLC-UV analysis was carried out on a 
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Hewlett Packard 1090 HPLC system equipped with a diode-array detector. 10 µL of the 
mother tincture were injected onto a reversed-phase column (C-18 Eurospher-100, 250 mm x 
4.6 mm, 5 µm). An isocratic method (60:40; A:B; v/v), with a flow rate of 0.8 mL/min, was 
used. The HPLC mobile phase consisted of acetonitrile mixed with 0.1% acetic acid (A) and 
water (B). The detection wavelength was 250 nm. 
 
2.11. Statistical analysis 
The U-test was used for the statistical analysis of the data obtained in the cell 
proliferation assay, colony forming ability test, comet assay, micronucleus assay and cell 
cycle analysis. The significance was tested as p<0.05 level. For the results of the DNA adduct 
analysis, signed rank test was used to analyze the differences from the solvent control. * 
p<0.05; ** p<0.01; *** p<0.001 was considered as statistically significant. 
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3. Results 
3.1. Cell proliferation 
The incorporation of BrdU during DNA synthesis in proliferating cells after 
incubation with 0-20 µg/mL AAI was analyzed. After 24 h AAI showed a concentration-
dependent inhibition of DNA synthesis in HepG2 cells (Fig. 2A). At a concentration of 20 
µg/mL AAI the DNA synthesis rate was decreased to about 25% relative to the solvent 
control. The proliferation assay was also used to determine the cytotoxicity of the mother 
tinctures of A. clematitis as well as A. europaeum containing AAI. After the addition of 
1.25% [v/v] of the mother tincture of A. clematitis a significant inhibition of DNA synthesis 
was observed (Fig. 2B). Taking into account the content of 52 µg AAI per mL mother tincture 
determined by HPLC-UV, 1.25% [v/v] correspond to a concentration of 0.65 µg/mL AAI. 
HepG2 cells treated with the mother tincture of A. europaeum also showed a significant 
decrease in proliferation. This was observed even at the lowest tested concentration of 0.25% 
[v/v] (Fig. 2C). Published by the Federal Institute for Drugs and Medical Devices (BfArM), 
the maximum amount of AAI in the mother tinctures of A. europaeum is 0.13 µg/g (Thiele, 
2010). Despite the lower content of AAI by a factor of 400 compared to A. clematitis tincture 
the mother tincture of A. europaeum was more cytotoxic in HepG2 cells. Both mother 
tinctures showed a higher cytotoxicity in comparison to the commercially available AAI, 
which may be due to other unknown components of the mother tinctures. 
 
3.2. Cell viability and colony forming ability 
Cell viability and colony forming ability were determined to examine the cytotoxic 
effects induced by AAI (Fig. 3). After treatment of HepG2 cells with up to 20 µg/mL AAI for 
6 or 24 h, no significant effect on cell viability (% control) was detectable. In contrast, there 
was a time- and concentration-dependent reduction of the colony forming ability. After 24 h 
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treatment with 10 µg/mL AAI the colony forming ability was reduced by approximately 50% 
and completely erased at 20 µg/mL AAI. A reduction of the colony forming ability was also 
observed at the shorter incubation period of 6 h; a reduction by 30% and 80% were seen at 10 
and 20 µg/mL AAI, respectively. These results indicate that AAI induces long-lasting 
cytotoxic effect in cells. 
 
3.3. Formation of DNA adducts 
DNA adduct formation was determined using the nuclease P1 enrichment version of 
the 32P-postlabeling method. HepG2 cells were treated with 0-20 µg/mL AAI for 6 or 24 h. 
The DNA adduct pattern induced by AAI on TLC consisted of two major adducts (Fig. 4A) 
which have been identified previously as 7-(deoxyadenosine-N6-yl)aristolactam I (dA-AAI) 
and 7-deoxyguanosine-N2-yl)aristolactam I (dG-AAI) (Arlt et al., 2011; Bieler et al., 1997). 
No DNA adducts were detectable in DNA from control cells treated with solvent (DMSO) 
only (data not shown). Quantitative 32P-postlabeling analysis revealed a time- and 
concentration-dependent formation of AAI-DNA adducts (Fig. 4B). After 6 h the total AAI-
DNA adduct level ranged from 7 to 229 adducts per 108 nucleotides and after 24 h from 15 to 
1043 adducts per 108 nucleotides. 
 
3.4. Induction of DNA strand breaks and FPG-sensitive sites 
To assess the induction of DNA strand breaks/alkali-labile sites and 
formamidopyrimidine DNA glycosylase (FPG)-sensitive sites by AAI, HepG2 cells were 
treated with 0 or 20 µg/mL AAI for 24 h and DNA damage was measured as % tail DNA 
using the single-cell gel electrophoresis (comet) assay in combination with the bacterial repair 
enzyme FPG. Only low levels of DNA damage were detected after AAI exposure in the 
absence of FPG (Fig. 5); at  20 µg/mL AAI a statistically significant increase in % tail DNA 
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was observed compared to solvent control (4.3 ± 2.6% versus 0.15 ± 0.15%). Furthermore, an 
induction of FPG-sensitive sites by AAI was detected; at 20 µg/mL AAI induced a 2.5-fold 
increase in % tail DNA relative to controls. 
 
3.5. Analysis of micronuclei formation 
HepG2 cells were treated with different concentrations of AAI for 6 or 24 h and 
micronuclei formation as well as cytotoxicity (replication index) was analyzed. A time- and 
concentration-dependent increase in micronuclei formation in binucleated cells was 
accompanied by increased cytotoxicity (Fig. 6). The formation of micronuclei was statistically 
significant at concentrations exceeding 30 µg/mL AAI at 6 h and 15 µg/mL at 24 h. 
Compared to background level, the micronuclei frequency increased more than 3-fold in cells 
treated with ≥ 15 µg/mL AAI for 24 h; the replication index was 49 ± 3% in cells treated with 
15 µg/mL AAI for 24 h. After 6 h the frequencies of micronucleated cells increased 2.2- and 
4.0-fold after treatment with 30 and 50 µg/mL AAI, respectively. The replication index after 
incubation with 30 µg/mL AAI for 6 h was 60 ± 12%. These observations are a strong 
indicator that AAI causes chromosome aberrations in HepG2 cells. 
 
3.6. Cell cycle analysis 
The DNA content of HepG2 cells exposed to 0-20 µg/mL AAI for 24 h was measured 
by FACS analysis (Fig. 7). There was a clear accumulation of cells in the S phase of the cell 
cycle after exposure to 10 or 20 µg/mL AAI, respectively. Arrest in the S phase implies that 
DNA synthesis is being inhibited in HepG2 cells in response to AAI exposure. 
 
3.7. Western blot analysis 
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The impact of AAI treatment on the p53, p21 and NQO1 protein levels was 
investigated by Western blotting (Fig. 8). Protein levels were analyzed in HepG2 cells treated 
with 0-20 µg/mL AAI for 24 h. P53 protein expression increased in a concentration-
dependent matter after AAI treatment. Similarly, an accumulation of p21 was found. 
Furthermore, NQO1 was expressed but only slightly induced after treatment with 20 µg/mL 
AAI. 
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4. Discussion 
In the present study we evaluated the cytotoxic and genotoxic effect of AAI in human 
hepatoma HepG2 cells. Earlier studies determined specific AA-DNA adducts in rodents and 
human tissues by 32P-postlabeling, especially the deoxyadenosine adduct 7-(deoxyadenosine-
N6-yl)aristolactam I (dA-AAI). This DNA adduct is characterized by a high persistence in the 
target tissue and leads to the induction of AA-characteristic A to T transversion mutations in 
target tissue (reviewed in Arlt et al., 2002b; Arlt et al., 2007). In HepG2 cells we could also 
detect a time- and concentration-dependent formation of AAI-DNA adducts by 32P-
postlabeling. One of the two main adducts detected was 7-(deoxyadenosine-N6-
yl)aristolactam I (dA-AAI). We showed that NQO1, which participates in AAI nitroreduction 
during metabolic activation (Stiborova et al., 2011), is expressed in HepG2 cells. We also 
found that AAI slightly induced NQO1 protein expression at the highest concentration. AAI 
may enhance its own metabolic activation through increased expression of NQO1. 
 Furthermore, AAI exposure resulted in an arrest of the HepG2 cells in S-phase of the 
cell cycle, indicating that interruption of DNA synthesis had occurred. Similar findings were 
observed previously in AAI-treated human colorectal carcinoma HCT116 cells (Simoes et al., 
2008). A concentration-dependent inhibition of DNA synthesis in HepG2 cells has also been 
observed in the cell proliferation assay. The pause in DNA synthesis is probably due to the 
intra-S checkpoint, which allows repair enzymes to recognize damaged DNA and to repair it, 
avoiding irreversible errors during replication. The intra-S-phase checkpoint is usually 
activated by damages encountered during the S-phase or by unrepaired damages that escapes 
the G1/S checkpoint and leads to an interruption of replication (Sancar et al., 2004). 
Broschard et al. (1994) showed that AA-DNA adducts block DNA replication. Therefore, it 
seems likely that AA-DNA adducts did not activate the G1/S checkpoint in HepG2 cells. 
Generally, the G1 arrest delays DNA damaged cells from progressing through the cell cycle, 
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avoiding accumulation of DNA damages by DNA repair or apoptosis (Sancar et al., 2004). 
Nevertheless, a concentration-dependent induction of p53 and p21 protein was demonstrated 
using Western blot analysis. Induction of p53 and p21 after AAI treatment has also been 
observed in previous studies (Arlt et al., 2011; Simoes et al., 2008). P53 and p21 proteins 
which are involved in the maintenance of the G1/S checkpoint also play a role in DNA repair 
mechanisms, so that the increased protein levels may be due to enhanced DNA repair. 
 In the comet assay only low levels of DNA strand breaks/alkali-labile sites were 
detected in HepG2 cells after AAI exposure in the absence of FPG. Wu et al. (2007) could 
also demonstrate the formation of DNA strand breaks/alkali-labile sites by AA in HepG2 
cells. Furthermore, we found an induction of FPG-sensitive sites by AAI in HepG2 cells 
suggesting that AAI may also induce oxidative damage to DNA. The bacterial repair enzyme 
FPG recognizes 7,8-dihydro-8-oxoguanine (8-oxoguanine; 8-OH-dG), 2,6-diamino-4-
hydroxy-5-formamindopyrimidine (Fapy-Gua), 4,6-diamino-5-formamido-pyrimidine (Fapy-
Ade) and to a smaller extent 7,8-dihydro-8-oxoadenine (8-oxoadenine) as well as 
apurinic/apyrimidinic sites (AP sites) and converts them into DNA strand breaks by its 
associated DNA endonuclease activity (Boiteux et al., 1992; Tchou et al., 1991). Wu et al. 
(2007), who applied immunoperoxidative staining, showed 8-OH-dG formation in AA-
exposed HepG2 cells. Further, Yu et al. (2011) showed that AAI induced oxidative stress-
related DNA damage through the activation of the MEK/ERK1/2 signaling pathway and the 
depletion of intracellular glutathione. The authors concluded that DNA breakage after 
treatment with AAI is partially caused by the formation of radical oxygen species. 
 The ability of AAI to cause chromosome aberrations was analyzed in the micronucleus 
assay. A time- and concentration-dependent increase in micronuclei formation accompanied 
by enhanced cytotoxicity expressed as replication index in HepG2 cells was observed. This is 
in agreement with other studies which have shown the formation of micronuclei in response 
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to AA (Kevekordes et al., 2001; Wu et al., 2007). To examine the acute as well as long-term 
cytotoxicity of AAI cell viability and colony forming ability was determined. Up to the 
highest AAI concentration tested no effect was observed on cell viability. In contrast, there 
was a time- and concentration-dependent reduction of colony forming ability probably due to 
the inhibition of DNA replication by AA-DNA adducts. Results of the proliferation assay 
demonstrated that there was a concentration-dependent decrease in proliferation of HepG2 
cells when treated with AAI. Also for the AAI-containing mother tinctures of A. clematitis 
and A. europaeum an inhibitory effect on cell proliferation was found which was, however, 
more pronounced. Comparing the inhibitory effect of the mother tinctures with the inhibition 
of DNA synthesis by the commercially available AAI it becomes clear that this effect is not 
attributable to AAI alone. Another well-known toxic substance found in the mother tincture 
A. europaeum is α-asarone (reviewed in Teuscher and Lindequist, 2010). In a recent study we 
showed that in the proliferation assay α-asarone exhibited a lower inhibition of the DNA 
synthesis than AAI at comparable concentrations (Unger and Melzig, 2012). The higher 
toxicity of the mother tinctures is probably due to other, not yet characterized toxic substances 
and/or synergistic interactions with other components. 
 There is increasing evidence that the plant extract AA and/or its major components 
(i.e. AAI) are responsible for the carcinogenic effects observed in humans who ingested 
Aristolochia plants or herbal medicines prepared from these plants (Schmeiser et al., 2009). 
Due to these findings, Aristolochia spp. and herbs that can be confused or substituted for 
Aristolochia have been banned in many countries. Unfortunately, these regulatory rules have 
been shown to be wholly inadequate in preventing exposure to AA (Gokmen and Lord, 2012; 
Gold and Slone, 2003), and there is growing evidence that AA exposure is causing a large 
unrecognized burden of disease in Asia with potentially devastating public health implications 
(Chen et al., 2012; Olivier et al., 2012). Therefore herbal medicines should be subjected to the 
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same stringent scrutiny and controls as drugs that undergo the standard development route 
before being launched on the market (Schmeiser et al., 2009). Increased efforts are made to 
assess the toxicity of herbal medicines (Ouedraogo et al., 2012) and our investigations 
provide a comprehensive example how to evaluate the impact of the plant component AAI on 
cell integrity. For this purpose we used the metabolically competent human hepatoma cell line 
HepG2 and analyzed the cytotoxic and genotoxic potential of AAI. Especially in the context 
for safe use of herbal remedies AA is a good example where improved regulation could help 
to eradicate a preventable disease − AAN. 
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Legends to figures: 
 
Figure 1: Metabolic activation and DNA adduct formation of AAI. 7-(deoxyadenosine-N6-
yl)aristolactam I (dA-AAI), 7-deoxyguanosine-N2-yl)aristolactam I (dG-AAI). 
 
Figure 2: Impact of (A) AAI as well as the mother tinctures of (B) Aristolochia clematitis and 
(C) Asarum europaeum on cell proliferation of HepG2 cells after 24 h exposure. Each bar 
represents the mean + SD of at least three independent experiments with six parallel samples. 
* p<0.05; *** p<0.001 Significantly different from the solvent control (U-test). 
 
Figure 3: Impact of AAI on cell number and colony forming ability of HepG2 cells after 
exposure for 6 h and 24 h. Values represent the mean + SD of at least three independent 
experiments with three parallel samples. Cell numbers are not significantly different from the 
solvent control (Kruskal-Wallis). # p<0.05; ** p<0.01; ***, ### p<0.001 Significantly 
different from the solvent control (U-test). 
 
Figure 4: DNA adduct formation measured by 32P-postlabeling in HepG2 cells after AAI 
exposure for 6 h and 24 h. (A) Autoradiographic profile of AAI-DNA adducts obtained after 
exposure to 20 µg/mL AAI for 6 h and 24 h. (B) Each bar represents the mean of total AAI-
DNA adducts (dA-AAI and dG-AAI) + SD of duplicate determinations of three independent 
experiments. AAI-DNA adducts were not detected in HepG2 control cells. * p<0.05 
Significantly different from the solvent control (signed rank test). dA-AAI: 7-
(deoxyadenosin-N6-yl)aristolactam I; dG-AAI: 7-(deoxyguanosin-N2-yl)aristolactam I. 
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Figure 5: Induction of DNA strand breaks and FPG-sensitive sites in HepG2 cells exposed to 
AAI for 24 h. Each bar represents the mean + SD of duplicate determinations of two 
independent experiments with two parallel samples. *** p < 0.001 Significantly different 
from the solvent control (U-test). FPG: formamidopyrimidine-DNA glycosylase. 
 
Figure 6: Induction of micronuclei in HepG2 cells exposed to AAI for (A) 6 h and (B) 24 h. 
Each bar represents the mean + SD of at least two independent experiments with two parallel 
samples. **, ## p<0.01; ***, ### p<0.001 Significantly different from the solvent control (U-
test). MN: micronucleated cells; BNC: binucleated cells; RI: replication index. 
 
Figure 7: Cell cycle analysis of HepG2 cells after exposure of AAI for 24 h using flow 
cytometry. Each bar represents the mean + SD of two independent experiments with three 
parallel samples. * p<0.05; ** p<0.01 Significantly different from the solvent control (U-
test). 
 
Figure 8: Western blot analysis of NQO1, p53 and p21 protein expression in HepG2 cells 
exposed to AAI for 24 h. β-actin protein expression was used as loading control. 
 
